X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
1. Dimethyl Dl-curine Dimethochloride
2. Dimethyl-l-curine Dimethochloride
3. Dimethyl-l-curine Dimethoiodide
4. Dimethylchondrocurarine
5. Dimethylcurarine Dimethochloride
6. Dimethylcurine
7. Dmcdm
8. Metocurine
9. Metocurine Dichloride
10. Metocurine Dichloride(1alpha)-isomer
11. Metocurine Dichloride, (1'alpha)-isomer
12. Metocurine Dichloride, (1beta)-(+-)-isomer
13. Metocurine Dihydroxide
14. Metocurine Diiodide
15. Metocurine Diiodide, (1beta)-(+-)-isomer
16. Metocurine Diiodide, (1beta)-isomer
17. Metocurine, (1'alpha)-isomer
18. Metocurine, (1beta)-isomer
19. Metubine
1. Metubine Iodide
2. 7601-55-0
3. Dimethyl Tubocurarine Iodide
4. Metocurine Iodide [usan]
5. Dimethylchondrocurarine Iodide
6. O,o'-dimethylchondrocurarine Diiodide
7. Dimethyltubocurarinium Iodide
8. Tubocuraranium, 6,6',7',12'-tetramethoxy-2,2,2',2'-tetramethyl-, Diiodide
9. Tetrandrini Dimethiodidum
10. (+)-o,o'-dimethylchondrocurarine Diiodide
11. Metocurine Iodide (usan)
12. O0u0e87x7f
13. Metubine
14. Methyl-curarin
15. Dsstox_cid_2944
16. Dimethylether Of D-tubocurarine Iodide
17. Methyl-curarin [german]
18. Dsstox_rid_76799
19. Dsstox_gsid_22944
20. (1s,16r)-9,10,21,25-tetramethoxy-15,15,30,30-tetramethyl-7,23-dioxa-15,30-diazoniaheptacyclo[22.6.2.23,6.18,12.118,22.027,31.016,34]hexatriaconta-3(36),4,6(35),8(34),9,11,18(33),19,21,24,26,31-dodecaene;diiodide
21. Cas-7601-55-0
22. Tubocurarine, O,o'-dimethyl-, Diiodide
23. Metubine Iodide (tn)
24. Nsc-36388
25. Einecs 231-510-3
26. Nsc 36388
27. Unii-o0u0e87x7f
28. Metocurine Iodide [usan:usp]
29. 6,6',7',12'-tetramethoxy-2,2,2',2'-tetramethyltubocuraranium Diiodide
30. Ncgc00181151-01
31. Chembl1739
32. 13h-4,6:21,24-dietheno-8,12-metheno-1h-pyrido(3',2':14,15)(1,11)dioxacycloeicosino(2,3,4-ij)isoquinolinium, 2,3,13a,14,15,16,25,25a-octahydro-9,18,19,29-tetramethoxy-1,1,14,14-tetramethyl-, Diiodide, (13ar-(13ar*,25as*))-
33. Schembl415745
34. Metocurine Iodide [mi]
35. Chebi:6901
36. Dtxsid9022944
37. Metocurine Iodide [vandf]
38. Metocurine Iodide [mart.]
39. Tox21_112755
40. Tox21_112755_1
41. Db00416
42. Metocurine Iodide [orange Book]
43. 2,2,2',2'-tetramethyl-6,6',7',12'-tetrakis(methyloxy)tubocuraran-2,2'-diium Diiodide
44. Ncgc00263444-01
45. 13h-4,6:21,24-dietheno-8,12-metheno-1h-pyrido(3',2':14,15)(1,11)dioxacycloeicosino(2,3,4-ij)isoquinolinium, 2,3,13a,14,15,16,25,25a-octahydro-9,18,19,29-tetramethoxy-1,1,14,14-tetramethyl-, Diiodide, (13ar,25as)-
46. Dimethyltubocurarinium Iodide [who-dd]
47. D00761
48. Q20817012
49. Tubocuraranium,6,6',7',12'-tetramethoxy-2,2,2',2'-tetramethyl-,diiodide
50. 13h-4,6:21,24-dietheno-8,12-metheno-1h-pyrido(3',2':14,15)(1,11)dioxacycloeicosino(2,3,4-ij)isoquinolinium, 2,3,13a,14,15,16,25,25a-octahydro-9,18,19,29-tetramethoxy-1,1,14,14-tetramethyl-, Iodide (1:2), (13ar,25as)-
| Molecular Weight | 906.6 g/mol |
|---|---|
| Molecular Formula | C40H48I2N2O6 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 4 |
| Exact Mass | 906.16018 g/mol |
| Monoisotopic Mass | 906.16018 g/mol |
| Topological Polar Surface Area | 55.4 Ų |
| Heavy Atom Count | 50 |
| Formal Charge | 0 |
| Complexity | 1060 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
For use as an anesthesia adjunct to induce skeletal muscle relaxation and to reduce the intensity of muscle contractions in convulsive therapy.
Metocurine iodide is a benzylisoquinolinium competitive nondepolarizing neuromuscular blocking agent. Metocurine iodide has a moderate risk of inducing histamine release and has some ganglion blocking activity. Metocurine iodide can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. As with other nondepolarizing neuromuscular blockers, the time to onset of paralysis decreases and the duration of maximum effect increases with increasing doses of metocurine iodide. Repeated administration of maintenance doses of metocurine iodide has no cumulative effect on the duration of neuromuscular block if recovery is allowed to begin prior to repeat dosing. Moreover, the time needed to recover from repeat doses does not change with additional doses. Repeat doses can therefore be administered at relatively regular intervals with predictable results.
Neuromuscular Nondepolarizing Agents
Drugs that interrupt transmission at the skeletal neuromuscular junction without causing depolarization of the motor end plate. They prevent acetylcholine from triggering muscle contraction and are used as muscle relaxants during electroshock treatments, in convulsive states, and as anesthesia adjuvants. (See all compounds classified as Neuromuscular Nondepolarizing Agents.)
3 to 4 hours
Metocurine iodide antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. This antagonism is inhibited, and neuromuscular block reversed, by acetylcholinesterase inhibitors such as neostigmine, edrophonium, and pyridostigmine.
Market Place
